Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CCKAR | P32238 | 3/20 | 0.38 |
| ▸ | CCKBR | P32239 | 3/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869960 | 0.80 | MME (0.51) | FPR2MME | |
| SCHEMBL3975272 | 0.80 | MME (0.51) | FPR2MME | |
| SCHEMBL3974459 | 0.78 | CTSB (0.49) | FPR2 | |
| SCHEMBL1935741 | 0.77 | MME (0.40) | TSHRMME | |
| SCHEMBL1935307 | 0.75 | PPARG (0.42) | TSHRMME | |
| SCHEMBL5739824 | 0.74 | ALDH1A1 (0.48) | — | |
| SCHEMBL28679142 | 0.74 | SLC7A5 (0.57) | — | |
| SCHEMBL3751045 | 0.74 | SLC7A5 (0.57) | — | |
| SCHEMBL2881400 | 0.73 | ACACB (0.46) | CA2MME | |
| SCHEMBL1156553 | 0.72 | GRN (0.32) | MMEGRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | APOB, LDLR, CETP | CA2 4881/4885CA1 4857/4885CCKAR 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.